Cerebrolysin in Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by complex pathologies including amyloid and tau accumulation, neuroinflammation, and impaired neurotrophic support.
• Cerebrolysin, a neuropeptide preparation, mimics endogenous neurotrophic factors and has demonstrated pleiotropic effects in experimental models of AD.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of Cerebrolysin in patients with Alzheimer's disease.
• To investigate the neurotrophic-like mode of action and potential signaling pathways involved in Cerebrolysin's effects.

Main Methods:

• Review of several randomized, double-blind, clinical trials evaluating Cerebrolysin in mild to moderate Alzheimer's disease patients.
• Experimental studies demonstrating Cerebrolysin's effects on AD-related pathologies and intracellular signaling pathways (e.g., PI3K/Akt/GSK-3β).

Main Results:

• Consistent benefits observed in global clinical function and cognition in AD patients treated with Cerebrolysin.
• Improvements in behavior at high doses and minor effects on daily living activities were noted.
• Clinical benefits were sustained post-treatment, supporting discontinuous administration.
• Cerebrolysin was generally well-tolerated with no significant adverse events.

Conclusions:

• Cerebrolysin demonstrates efficacy as monotherapy for Alzheimer's disease, offering benefits in cognition and function.
• The drug's neurotrophic-like action, potentially involving the PI3K/Akt/GSK-3β pathway, contributes to its therapeutic effects.
• Cerebrolysin is a promising option for both monotherapy and combined therapy in Alzheimer's disease management.